Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer

Technology appraisal guidance
Reference number: TA258
Published: 27 June 2012

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): NCRI/Royal College of Physicians/RCR/ACP/JCCO

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): NCRI/Royal College of Physicians/RCR/ACP/JCCO

Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line): NCRI/Royal College of Physicians/RCR/ACP/JCCO
10 May 2012
(259.24 Kb 15 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 08 May 2012